Typherix + NVGH Vi-CRM197

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Typhoid Fever

Conditions

Typhoid Fever

Trial Timeline

May 1, 2010 → Nov 1, 2010

NCT ID

NCT01123941

About Typherix + NVGH Vi-CRM197

Typherix + NVGH Vi-CRM197 is a phase 1 stage product being developed by Novartis for Typhoid Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01123941. Target conditions include Typhoid Fever.

What happened to similar drugs?

0 of 1 similar drugs in Typhoid Fever were approved

Approved (0) Terminated (0) Active (1)

🔄Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCVZydus LifesciencesPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01123941	Phase 1	Completed	May 1, 2010	Nov 1, 2010	Typhoid Fever

Competing Products

7 competing products in Typhoid Fever

See all competitors

Product	Company	Stage	Hype Score
Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV	Zydus Lifesciences	Phase 3	47
Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine	Novartis	Phase 2	35
NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine	Novartis	Phase 2	35
NVGH Vi-CRM197	Novartis	Phase 2	35
Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine	Novartis	Phase 2	35
Vivotif	Bavarian Nordic	Pre-clinical	23
Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4)	Emergent BioSolutions	Phase 2	25